Author Archives: admin


Stem Cell Clinic > Articles by: admin

Prediction of off-target specificity and cell-specific fitness of CRISPR-Cas System using attention boosted deep learning and network-based gene…

By Uncategorized

CRISPR-Cas is a powerful genome editing technology and has a great potential forin vivo gene therapy. Successful translational application of CRISPR-Cas to biomedicine still faces many safety concerns, including off-target side effect, cell fitness problem after CRISPR-Cas treatment, and on-target genome editing side effect in undesired tissues. To solve these issues, it is needed to design sgRNA with high cell-specific efficacy and specificity. Existing single-guide RNA (sgRNA) design tools mainly depend on a sgRNA sequence and the local information of the targeted genome, thus are not sufficient to account for the difference in the cellular response of the same gene in different cell types. To incorporate cell-specific information into the sgRNA design, we develop novel interpretable machine learning models, which integrate features learned from advanced transformer-based deep neural network with cell-specific gene property derived from biological network and gene expression profile, for the prediction of CRISPR-Cas9 and CRISPR-Cas12a efficacy and specificity. In benchmark studies, our models significantly outperform state-of-the-art algorithms. Furthermore, we find that the network-based gene property is critical for the prediction of cell-specific post-treatment cellular response. Our results suggest that the design of efficient and safe CRISPR-Cas needs to consider cell-specific information of genes. Our findings may bolster developing more accurate predictive models of CRISPR-Cas across a broad spectrum of biological conditions as well as provide new insight into developing efficient and safe CRISPR-based gene therapy.

Read more here:
Prediction of off-target specificity and cell-specific fitness of CRISPR-Cas System using attention boosted deep learning and network-based gene...

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic…

By Induced Pluripotent Stem Cells

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma

Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales

SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic T cell therapies for the treatment of diseases of high unmet need, today announced an exclusive worldwide collaboration and license agreement to research and develop induced pluripotent stem cell (iPSC) AlloCAR therapy products for initial application in non-Hodgkin lymphoma, leukemia and multiple myeloma. Under the partnership, Allogene and Notch will create allogeneic cell therapy candidates from T cells or natural killer (NK) cells using Notchs Engineered Thymic Niche (ETN) platform.

Notch was established in 2018 by Juan Carlos Ziga-Pflcker, Ph.D. and Peter Zandstra, Ph.D., recognized pioneers in iPSC and T cell differentiation technology. Notch is developing a next-generation approach to differentiating mature immune cells from iPSCs. The Notch ETN technology platform offers potential flexibility and scalability for the production of stem cell-derived immune cell therapies. iPSCs may provide renewable starting material for AlloCAR T therapies that could allow for improved efficiency of gene editing, greater scalability of supply, product homogeneity and more streamlined manufacturing.

This collaboration exemplifies Allogenes long-term commitment to advancing the field of cancer treatment as we continue to expand and progress our innovative pipeline of off-the-shelf AlloCAR candidates, said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics. The scientific founders of Notch Therapeutics are among the most respected experts in the field of stem cell biology and its applications to generating T cells and other functional immune cells. We are confident that their technology and expertise, combined with Allogenes leadership in AlloCAR therapies, has the potential to unlock future generations of cell therapy treatments for patients.

Renewable-source, off-the-shelf cell therapies that may produce cells with greater consistency and at industrial scale have long been the dream for people working in this field, said Ulrik Nielsen, Ph.D., Executive Chairman of Notch. We are delighted to spring into the research collaboration for iPSC-based AlloCAR therapies with Allogene, a leader in the allogeneic CAR T field, with the goal of expanding options for patients.

Under the terms of the agreement, Notch will be responsible for preclinical research of next-generation iPSC AlloCAR T cells. Allogene will clinically develop the product candidates and holds exclusive worldwide rights to commercialize resulting products. Allogene will provide to Notch an upfront payment of $10 million. Notch will be eligible to receive up to $7.25 million upon achieving certain agreed research milestones, up to $4.0 million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283 million per exclusive target and cell type upon achieving certain clinical, regulatory and commercial milestones as well as tiered royalties on net sales in the mid to high single digits. In addition to this collaboration and license agreement, Allogene has acquired a 25 percent equity position in Notch and will assume a seat on Notchs Board of Directors.

Master cell banks of genetically modified, induced pluripotent stem cells could provide an inexhaustible source of cell therapies that may improve outcomes and expand applicability to new areas, said Notch Co-Founder Juan Carlos Ziga-Pflcker, Ph.D., a senior scientist at Sunnybrook Research Institute and a Professor and Chair of the Department of Immunology at the University of Toronto.

This work with Allogene may also pave the way for additional off-the-shelf cell therapeutics that are custom-designed to treat other immunity-related diseases such as infectious diseases, autoimmune diseases and aging, said Notch Co-Founder and Chief Scientific Officer Peter Zandstra, Ph.D., a Professor at the University of British Columbia and University of Toronto.

About Notch Therapeutics (www.notchtx.com)Notch is an immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of diseases of high unmet medical need. Notchs technology platform uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver safer, consistently manufactured and more cost-effective cell immunotherapies to patients. At the core of Notchs technology is the synthetic Engineered Thymic Niche (ETN) platform, which drives the expansion and differentiation of stem cells in scalable, fully defined, feeder-free and serum-free cultures into T cells that can be genetically tailored for any T cell-based immunotherapeutic application. This technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Center for Commercialization of Regenerative Medicine (CCRM) in Toronto.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer. Led by a world-class management team with significantexperience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell therapycandidates with the goal of delivering readily available cell therapy on-demand, more reliably, and atgreater scale to more patients. For more information, please visitwww.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to progress the research collaboration, Notchs ability to develop a next-generation approach to differentiating mature immune cells from iPSCs, the ability to develop and manufacture new therapies from Notch technology, and the potential benefits of Notch technology and AlloCAR T therapy. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with theSecurities and Exchange Commission(SEC), including without limitation in its Form 10-Q for the quarter endedJune 30, 2019. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Notch Media Contact:Mary MoynihanM2Friend Biocommunications802-951-9600mary@m2friend.com

The rest is here:
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic...

MD Anderson and Takeda Team Up on Next-Generation Immuno-Oncology Therapeutics – BioSpace

By Induced Pluripotent Stem Cells

The University of Texas MD Anderson Cancer Center has partnered with Takeda Pharmaceutical on immuno-oncology therapies. Specifically, they announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies. They say these CAR-NK therapies will be armored with IL-15 to treat B-cell and other cancers.

Under the deal, Takeda will access MD Andersons CAR-NK technology platform and pick up the exclusive rights to develop and commercialize up to four programs. Those programs include a CD19-targeted CAR-NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR-NK therapy. They will collaborate on research to advance the programs.

Our vision is to improve upon existing treatments by developing armored CAR NKs that could be administered off-the-shelf in an outpatient settingenabling more patients to be treated effectively, quickly and with minimal toxicities, said Katy Rezvani, professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson. With their expertise in hematologic malignancies and commitment to developing next-generation cell therapies, Takeda is the ideal collaborator to help our team advance CAR NK-cell therapies to patients in need of treatments.

MD Andersons allogeneic CAR NK technology platform collects umbilical cord blood, isolates NK cells for it, and then engineers those NK cells to express CARs against specific cancer targets. They utilize a retroviral vector to deliver genes to the CAR NK cells, which both improves their effectiveness and fine-tunes them for specific cancer cells. The CD19 CAR makes the cells even more specific for B-cell malignancies, and the IL-15 improves the proliferation and survival of the CAR-NK cells in the body.

Currently approved CAR-T therapies, which essentially means Novartis Kymriah (tisagenlecleucel) and Gilead Sciences Yescarta (axicabtagene ciloleucel), isolate T-cells from the patients blood, which are then engineered to express CARs against the patients specific cancer. The downside to this is that it is time-consuming, taking several weeks. So this approach, which others are also working to develop, would be more of a one-size-fits-all therapy that could be used to treat the patient immediately rather than uniquely engineer the CARs.

MD Anderson and Takeda expect their CD19 CAR NK therapy could be administered in an outpatient setting. There is an ongoing Phase I/IIa trial in patients with relapsed and refractory B-cell cancers. In it, there has been little or no evidence of the severe cytokine release syndrome (CRS) or neurotoxicity associated with Kymriah and Yescartaalthough those companies and the affiliated healthcare practitioners have developed protocols for minimizing those effects.

As well as developing the CAR NK-cell therapies, Takeda and its partners are working to improve the safety, efficacy and accessibility of the first-generation CAR-Ts, including gamma delta CAR-Ts, induced pluripotent stem cell-derived CAR-Ts, CAR-Ts that target solid tumors, and other approaches.

Takeda reportedly hopes to advance five oncology cell therapies into the clinic by the end of fiscal year 2020.

Under the agreement, Takeda will handle development, manufacturing and commercialization of CAR-NK products that come out of the partnership. MD Anderson will receive an undisclosed upfront payment and be eligible for various milestones for each target in addition to tiered royalties on net sales of any products that come out of the deal.

MD Andersons CAR-NK platform is led by Rezvani and supported by the adoptive cell therapy platform, Chronic Lymphocytic Leukemia Moon Shot and B-Cell Lymphoma Moon Shot, which are all part of MD Andersons Moon Shots Program.

MD Andersons CAR-NK platform represents the curative potential of cell therapies, which is why we are establishing the CD19 CAR NK as our lead cell therapy candidate in oncology, said Andy Plump, president of Research and Development at Takeda. We need to work swiftly and with purpose, and as such, we intend to initiate a pivotal study of the CD19 CAR NK in 2021.

Visit link:
MD Anderson and Takeda Team Up on Next-Generation Immuno-Oncology Therapeutics - BioSpace

Goldfinch Bio to Present Oral and Poster Presentations at the American Society of Nephrology Kidney Week 2019 Annual Meeting – BioSpace

By Induced Pluripotent Stem Cells

Nov. 5, 2019 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it will present one oral and two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting, taking place November 5-10, 2019, in Washington, D.C.

The oral presentation will address the ways in which Goldfinch Bios platform generates induced pluripotent stem cell (iPSC)-derived human podocytes and kidney organoids to enable target validation and preclinical assessment of prospective therapies for kidney disease. The poster presentations will include data on how GFB-887, a sub-type selective, small molecule transient receptor potential canonical 5 (TRPC5) ion channel inhibitor, was effective in reducing proteinuria in animal models of focal segmental glomerulosclerosis (FSGS) and other kidney diseases, as well as data on how Goldfinch Bios proprietary Kidney Genome AtlasTM can be leveraged to unravel molecular mechanisms of kidney diseases.

Details are as follows:

Abstract Title: GFB-887, a Small Molecule Inhibitor of TRPC5, Attenuates Proteinuria in Animal Models of FSGS, Minimal Change Disease, and Diabetic Nephropathy (poster presentation)Session Title: Glomerular Diseases: Podocyte Biology IPresenter: John F. Reilly, Ph.D., Goldfinch BioDate/Time: Thursday, November 7, 2019, from 10:00 a.m. to 12:00 p.m. ETLocation: Exhibit Hall, Walter E. Washington Convention CenterAbstract Number: TH-PO1063

Abstract Title: An iPSC platform for Human Preclinical Evaluation of Kidney Disease Targeting Compounds (oral presentation)Session Title: Glomerular Diseases: Technologies, Mechanisms, and TherapeuticsPresenter: Amy Duyen Westerling-Bui, Ph.D., Goldfinch BioDate/Time: Saturday, November 9, 2019, 5:30 p.m. to 5:42 p.m. ETLocation: 201, Walter E. Washington Convention CenterAbstract Number: SA-OR053

Abstract Title: Unraveling the Genetic Contributions to Kidney Disease with the Kidney Genome Atlas (poster presentation)Session Title: Genetic Diseases of the Kidney - IIIPresenter: Thomas Soare, Ph.D., Goldfinch BioDate/Time: Saturday, November 9, 2019, 10:00 a.m. to 12:00 p.m. ETLocation: Exhibit Hall, Walter E. Washington Convention CenterAbstract Number: SA-PO408

About the Kidney Genome AtlasTM

Goldfinch Bios Kidney Genome Atlas (KGA) is the most comprehensive patient registry to investigate the underlying mechanisms of kidney disease. Through the combination of genomic, transcriptomic and proteomic data with thousands of anonymized clinical patient profiles, Goldfinch Bio is able to conduct unprecedented analyses to elucidate pathways and novel targets for kidney disease.

In May 2019, Goldfinch Bio entered into a strategic collaboration with Gilead Sciences, Inc. to sequence 80,000 diabetic kidney disease (DKD) patients and diabetic controls. Goldfinch Bio received a $55 million upfront payment, including a $5 million equity investment, and a commitment of an additional $54 million to support the development of the KGA platform for DKD. Goldfinch Bio will validate targets and support discovery and development of products to which Gilead will have exclusive option rights in exchange for additional milestone payments.

About GFB-887

GFB-887 is a sub-type selective, small molecule transient receptor potential canonical 5 (TRPC5) ion channel inhibitor in clinical development for the treatment of focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD) and diabetic nephropathy (DN). The ongoing Phase 1 study is evaluating the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers.

TRPC5 is a calcium-permeable ion channel implicated in the pathogenesis of kidney disease. Recent evidence has demonstrated that TRPC5 and Rac1, a critical regulator of cellular motility, form a vicious cycle that drives pathogenic remodeling of the actin cytoskeleton in podocytes. This causes podocyte loss and breach of the filtration barrier, leading to proteinuria, the hallmark of progressive kidney diseases such as FSGS, TR-MCD and DN. Inhibition of TRPC5 offers a potential point of therapeutic intervention to restore podocyte integrity and halt progression of these diseases.

About FSGS, TR-MCD and DN

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder and histopathologic diagnosis characterized by scarring of the kidney's filtering units, or glomeruli, leading to proteinuria, an excess of essential proteins spilling into the urine. FSGS is associated with loss of podocytes, terminally differentiated cells of the kidney glomeruli essential for filtration and proper kidney function. Recent research into the genetics of kidney disease has identified over 50 genes associated with FSGS and implicates the podocyte as a central player in the pathogenesis of FSGS. There are currently no FDA-approved treatments available for patients with FSGS.

Similar to FSGS, treatment-resistant minimal change disease (TR-MCD) is a rare kidney disorder characterized by podocyte injury and is an important cause of nephrotic syndrome in children as well as adults. Clinical hallmarks of MCD include rapid onset of edema and weight gain. While MCD may be managed with corticosteroids, a subset of patients fail to respond and are considered treatment-resistant. There are currently no FDA-approved treatments available for patients with TR-MCD.

Diabetic nephropathy (DN) develops in approximately 30 to 40 percent of patients who have diabetes and is a leading cause of end-stage kidney disease, cardiovascular disease and early mortality worldwide. Despite current therapies, the number of people with DN continues to increase, highlighting the need for additional treatments that preserve kidney function.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company that leverages a genomics-based, precision medicine approach to discovering and developing kidney disease treatments. Its Kidney Genome AtlasTM is a proprietary biology platform that drives candidate discovery, patient selection and biomarker development. The Companys lead candidate, GFB-887, is a transient receptor potential canonical 5 (TRPC5) ion channel inhibitor being evaluated in a Phase 1 clinical trial for the treatment of kidney diseases. Goldfinch Bio is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody, for the treatment of rare and metabolic kidney diseases, which it licensed from Takeda Pharmaceutical Company Limited in October 2019. The company expects to submit an IND for GFB-024 in 2H 2020. Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc. For more information about Goldfinch Bio, visit http://www.goldfinchbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005206/en/

View original post here:
Goldfinch Bio to Present Oral and Poster Presentations at the American Society of Nephrology Kidney Week 2019 Annual Meeting - BioSpace

International Conference on Stem Cells and Regenerative Medicine – Hoover Sun

By Stell Cell Research

Join us! To furnish your research and ideas and to examine your interpretation at International Conference on Stem Cells and Regenerative Medicine which is scheduled on November 06 - 07, 2019 at Tokyo, Japan.

Stem Cells 2019 provides you with a unique platform to share your generous thoughts and ideas related to your research and it adds a valuable acknowledgment to your profile.

The conference is based on the theme of Novel Techniques in Stem Cells and Regenerative Medicine. Based on this, we are delighted to have your presence at our conference.

Highlights include: Stem Cells, Regenerative Medicine, Tissue Regeneration, Therapeutic Cloning, and Stem Cell Transplantation which is detailed in Stem cells

To Visit our conference webpage: http://stemcells.pulsusconference.com/

Hope you will join hands with us to encourage Stem Cells research to have a better tomorrow.

We look forward to receiving a favorable consideration from you.

Explore the evidence to make a difference!

Best Regards,

Veronica Carter

Program Manager | Stem Cells 2019

E: stemcellresearch(at)pulsusglobalevents(dot)com

Ph: 44-203-769-1778

Read this article:
International Conference on Stem Cells and Regenerative Medicine - Hoover Sun

Lymphatic System Discovered To Play Key Role in Hair Regeneration – Technology Networks

By Stell Cell Research

Given the amount of wear and tear its subjected to on a daily basis, the skin has a phenomenal ability to replenish itself. Spread throughout it are small reservoirs of stem cells, nested within supportive microenvironments called niches, which keep a tight rein on this repair process. Too much tissue might cause problems like cancer, while too little might accelerate aging.

Until now, scientists were uncertain whether the stem cells themselves could instruct other stem cells to form new skin by reshaping their niche. But new research in Science, led by Elaine Fuchs, the Rebecca C. Lancefield Professor, indicates that stem cells can indeed influence tissue regeneration. The study identifies a molecular coordination tool used by stem cells to signal across niches.

The researchers also discovered a new component of the niche: a specialized type of vessel called lymphatic capillaries, which transport immune cells and drain excess fluids and toxins from tissues. These capillaries form an intimate network around the stem cell niche within each hair follicle, the study showed, thereby interconnecting all its niches.

By turning the skin completely transparent, says postdoctoral fellow Shiri Gur-Cohen, we were able to reveal the complex architecture of this network of tubes.

Hair-follicle stem cells control the behavior of lymphatic capillaries by secreting molecules that act as an on-off switch for drainage, the scientists found, enabling them to control the composition of fluids and cells in the surrounding locale and ultimately synchronize regeneration across the tissue.

The involvement of the lymphatic system in this process is a new concept, says Fuchs, and might potentially provide new therapeutic targets for lymph-related conditions such as wound-healing defects and hair loss.

Reference

Gur-Cohen et al. (2019) Stem celldriven lymphatic remodeling coordinates tissue regeneration. Science. DOI: https://doi.org/10.1126/science.aay4509

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to see the original:
Lymphatic System Discovered To Play Key Role in Hair Regeneration - Technology Networks

Global Cancer Stem Cell Market Forecast to 2024 by Types, Application and by Regions – Exchange 99

By Stell Cell Research

Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through generation of new tumor. Thus, with advancement in technology especially in cancer stem cells research area, therapies specific to targeting cancer stem cells are expected to improve quality of life and survival cases of cancer patients with metastatic diseases.

Access Report Details at: https://www.themarketreports.com/report/global-cancer-stem-cell-market-by-manufacturers-countries-type-and-application-forecast

Market share of global Cancer Stem Cell industry is dominate by companies like Thermo Fisher Scientific, Inc., AbbVie, Inc.. Merck KGaA, Bionomics, Lonza, Stemline Therapeutics, Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., OncoMed Pharmaceuticals, Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME, Inc. and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).

With the help of 15 chapters spread over 100 pages this report describe Cancer Stem Cell Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Cancer Stem Cell, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Cancer Stem Cell sales channel, distributors, traders, dealers, and research findings completes the global Cancer Stem Cell market research report.

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

Cell Culturing

Cell Separation

Cell Analysis

Molecular Analysis

Others

Market Segment by Applications, can be divided into

Stem Cell Based Cancer Therapy

Targeted CSCs

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1492166

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Cancer Stem Cell Market Competitions, by Manufacturer

4 Global Cancer Stem Cell Market Analysis by Regions

5 North America Cancer Stem Cell by Countries

6 Europe Cancer Stem Cell by Countries

7 Asia-Pacific Cancer Stem Cell by Countries

8 South America Cancer Stem Cell by Countries

9 Middle East and Africa Cancer Stem Cell by Countries

10 Global Cancer Stem Cell Market Segment by Type

11 Global Cancer Stem Cell Market Segment by Application

12 Cancer Stem Cell Market Forecast (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1492166

More:
Global Cancer Stem Cell Market Forecast to 2024 by Types, Application and by Regions - Exchange 99

Stem cell transplants approved for people with MS in Scotland – MS Trust

By Stell Cell Research

The Scottish Health Technologies Group (SHTG), which gives advice to NHS Scotland on new treatments, has approved autologous haematopoietic stem cell transplantation (AHSCT) for people with highly active relapsing remitting MS (RRMS).

After carrying out an in-depth review, the SHTG concluded that AHSCT should be considered as a treatment option for people with RRMS who continue to have relapses and show MS activity on MRI scans despite taking the most effective disease modifying drugs. They also emphasised that it was important for people to be aware of the risks and demanding nature of the treatment as well as the benefits.

SHTG looked at the evidence for using AHSCT in MS and invited submissions from patient groups, including the MS Trust. In our report, we highlighted the impact that RRMS has on all aspects of life, the experiences of people with MS who have benefited from NHS treatment with AHSCT in England, and argued that people living in Scotland should not be denied access to this treatment option.

What does this mean for me?

At the moment, there are no centres in Scotland offering stem cell treatments for MS. Two centres in England (Sheffield and London Collaborative Group) provide AHSCT as an NHS treatment for a limited number of people who meet strict eligibility criteria.

The decision from Scottish Health Technologies Group to approve AHSCT is very welcome news but this is thefirst step towards making this treatment available in Scotland. NHS Scotland is required to consider this advice and we will continue to press for access to AHSCT for people meeting the eligibility criteria in Scotland.

Link:
Stem cell transplants approved for people with MS in Scotland - MS Trust

Johns Hopkins professor to lecture on interplay of secular bioethics, religion as part of Honors Colloquium – URI Today

By Stell Cell Research

KINGSTON, R.I. Nov. 4, 2019 As part of this years Religion in America Honors Colloquium, Dr. Jeremy Sugarman will visit the University of Rhode Island to share his thoughts on the inevitable tangling of religion and medicine, and the ethical issues that arise when religious and secular values collide. He will also discuss the emergence of secular bioethics, and spend time analyzing a real-world example.

The lecture, Ethical Controversies in Medicine and Medical Research: The Interplay of Secular Bioethics and Religion, will take place Tuesday, Nov. 12, at 7 p.m. in Edwards Hall, 64 Upper College Road, on the Kingston Campus. This event will not be livestreamed, nor will it be archived. It is free and open to the public.

Sugarman is an internationally recognized leader in the field of biomedical ethics, and has particular expertise in applying empirical methods and evidence-based standards to evaluate and analyze bioethical issues. He is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Berman Institute of Bioethics at the Johns Hopkins University.

In the past, Sugarman has researched and made contributions to medical ethics and policy, including but not limited to his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research and global health and research oversight. Sugarman is the author of more than 300 articles, reviews and book chapters.

Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He served as senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission. Sugarman is a member of the Scientific and Research Advisory Board for the Canadian Blood Service and the Ethics and Public Policy Committees of the International Society for Stem Cell Research. He is co-chair of the Johns Hopkins Institutional Stem Cell Research Oversight Committee. In addition, he is chair of the Ethics Working Group of the HIV Prevention Trials Network and co-leads the Ethics and Regulatory Core of the NIH Health Care Systems Research Collaboratory.

Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, the Association of American Physicians, and the Institute of Medicine. He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center.

Lauren Poirier, an intern in the Marketing and Communications Department at URI and public relations and English major, wrote this press release.

See more here:
Johns Hopkins professor to lecture on interplay of secular bioethics, religion as part of Honors Colloquium - URI Today

Latest Report on Stem Cell Banking Market to Drive Amazing Growth by 2025 | Cord Blood Registry (CBR) Systems – News Hours Today

By Stell Cell Research

Recent research and the current scenario as well as future market potential ofGlobal Stem Cell Banking Market Is Expected to Reach Around USD 13.36 Billion By 2025.The global Stem Cell Banking Market report provides significant information about Stem Cell Banking Market by fragmenting the market into different segments. GlobalStem Cell Banking MarketReport concentrates on the strong analysis of the present state ofStem Cell Banking Marketwhich will help the readers to develop innovative strategies that will act as a catalyst for the overall growth of their industry.(Sample Copy Here)This research report segments theStem Cell Banking Marketaccording to Type, Application and regions.It highlights the information about the industries and market, technologies, and abilities over the trends and the developments of the industries. After deep research and analysis by the experts, they also disclosed the data about the strong contenders contributing in the market growth and expansion and challenging one another in terms of demand, supply, production, value estimation, revenue, and sales.

Request For Free Sample ofStem Cell Banking MarketReport:www.zionmarketresearch.com/sample/stem-cell-banking-market

Along with the elaborated information about the key contenders, the globalStem Cell Banking Marketreport efficiently provides information by segmenting the market on the basis of the type services and products offerings, form of the product, applications of the final products, technology on which the product is based, and others. The report is also bifurcated the market on the basis of regions to analyze the growth pattern of the market in different geographical areas.

The Leading Market Players Covered in this Report are : Cord Blood Registry (CBR) Systems, Cordlife Group Limited, Cryo-Cell International, ViaCord, Cryo-Save, LifeCell International, StemCyte, Global Cord Blood Corporation, Vita34, Smart Cells International, and CryoHoldco

TheStem Cell Banking Marketcomprehensively describes the market and prognosticates it to depict a highly illustrious growth during the forthcoming years. The report offers in-depth analysis of current and futureStem Cell Banking Marketoutlook across the globe. The report is projected to help readers with the regions that are expected to witness fastest growth during the forecast period. Along with this, the compilation is intended to help readers with the thorough analysis of recent trend, competitive landscape of the globalStem Cell Banking Marketduring the forecast period.Get Free Brochure ofStem Cell Banking MarketReport:www.zionmarketresearch.com/requestbrochure/stem-cell-banking-market

The Stem Cell Banking Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Stem Cell Banking Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

Abstract

The report covers the conjecture and investigation for the Stem Cell Banking Market on a worldwide and provincial level.

The report incorporates the positive and the negative factors that are impacting the development of the market.

All the sections have been assessed dependent on the present and the future patterns.

The report incorporates the definite organization profiles of the noticeable market players.

Browse Press Release@www.zionmarketresearch.com/news/stem-cell-banking-market

he global Stem Cell Banking Market report conveys the information regarding the prcised escalation or decline in market growth due to several key factors. The analysts, using various analytical methodologies such as probability, SWOT analysis, among others to generate the precise forecast belonging to the growth rate and upcoming opportunities in the market growth at the global level. The global Stem Cell Banking Market report represents the complete information of the market in an eye-catching and easily understandable way with examples, figures, graphs, and flowcharts.

This report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price ofStem Cell Banking Market, revenue and market share, for key manufacturers.

Following 15 Chapters represents the Stem Cell Banking Market globally:

Chapter 1,enlist the goal of global Stem Cell Banking Market covering the market introduction, product image, market summary, development scope,Stem Cell Banking Market presence;

Chapter 2,studies the key global Stem Cell Banking Market competitors, their sales volume, market profits and price of Stem Cell Banking Market in 2016 and 2025;

Chapter 3,shows the competitive landscape view of global Stem Cell Banking Market on the basis of dominant market players and their share in the market growth in 2016 and 2025;

Chapter 4,conducts the region-wise study of the global Stem Cell Banking Marketbased on the sales ratio in each region, and market share from 2016 to 2025;

Chapter 5,6,7,8 and 9demonstrates the key countries present in these regions which have revenue share in Stem Cell Banking Market;

Chapter 10 and 11describes the market based on Stem Cell Banking Market product category, wide range of applications, growth based on market trend, type and application 2016 to 2025;

Chapter 12shows the global Stem Cell Banking Market plans during the forecast period from 2016 to 2025 separated by regions, type, and product application.

Chapter 13, 14, 15mentions the global Stem Cell Banking Market sales channels, market vendors, dealers, market information and study conclusions, appendix and data sources.

The classification of the global Stem Cell Banking Market is done based on the product type, segments, and end-users. The report provides an analysis of each segment together with the prediction of their development in the upcoming period. Additionally, the latest research report studies various segments of the global Stem Cell Banking Market in the anticipated period.

Also, Research Report Examines:

Lastly, with a team of vivacious industry professionals, we offer our clients with high-value market research that, in turn, would aid them to decipher new market avenues together with new strategies to take hold of the market share.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Browse for more Research Reports:fnfresearch.com

See more here:
Latest Report on Stem Cell Banking Market to Drive Amazing Growth by 2025 | Cord Blood Registry (CBR) Systems - News Hours Today

→←